Myriad Genetics Stock Price, News & Analysis (NASDAQ:MYGN)

$32.88 -0.53 (-1.59 %)
(As of 11/17/2017 06:58 AM ET)
Previous Close$33.41
Today's Range$32.44 - $33.37
52-Week Range$15.15 - $37.30
Volume956,880 shs
Average Volume1.22 million shs
Market Capitalization$2.31 billion
P/E Ratio28.77
Dividend YieldN/A
Beta0.24

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.


Industry, Sector and Symbol:
  • Industry: Medical Diagnostic & Testing Equipment
  • Sub-Industry: Biotechnology
  • Sector: Medical Diagnostic & Testing Equipment
  • Symbol: NASDAQ:MYGN
  • CUSIP: 62855J10
  • Web: www.myriad.com
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 2.34%
  • Quick Ratio: 2.06%
Price-To-Earnings:
  • Trailing P/E Ratio: 28.77
  • Forward P/E Ratio: 31.31
  • P/E Growth: 1.99
Sales & Book Value:
  • Annual Sales: $771.4 million
  • Price / Sales: 2.95
  • Cash Flow: $1.86 per share
  • Price / Cash: 17.70
  • Book Value: $12.57 per share
  • Price / Book: 2.62
Profitability:
  • Trailing EPS: $1.48
  • Net Income: $21.8 million
  • Net Margins: 13.28%
  • Return on Equity: 9.54%
  • Return on Assets: 5.97%
Misc:
  • Employees: 2,400
  • Outstanding Shares: 69,240,000
 

Frequently Asked Questions for Myriad Genetics (NASDAQ:MYGN)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, November, 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.05. The firm had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 earnings per share. View Myriad Genetics' Earnings History.

When will Myriad Genetics make its next earnings announcement?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY18 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.03. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $765.01 million.Myriad Genetics also updated its Q2 guidance to $0.22-0.24 EPS.

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2017?

10 brokers have issued 1-year target prices for Myriad Genetics' stock. Their forecasts range from $16.00 to $40.00. On average, they expect Myriad Genetics' share price to reach $26.56 in the next twelve months. View Analyst Ratings for Myriad Genetics.

What are Wall Street analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Myriad Genetics has been trading above the broader industry. While we await the company to release its first quarter fiscal 2018 results, we expect it to deliver another quarter of strong topline on the back of solid growth in EndoPredict and GeneSight testing revenues. Also, the company witnessed a third consecutive quarter of rise in hereditary cancer volumes. We are currently upbeat about the receipt of positive coverage decision for EndoPredict tests from Palmetto GBA. Also, it received provincial reimbursement in Quebec for the same.  Recently, the company introduced riskScore under its myRisk Hereditary Cancer testing portfolio.  On the flip side, a dull operating margin scenario owing to a rise in operating expenses is disappointing. Currency fluctuations and stiff competition are other major headwinds for the company." (10/17/2017)
  • 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:

  • John T. Henderson M.D., Independent Chairman of the Board (Age 73)
  • Mark C. Capone, President, Chief Executive Officer, Director (Age 55)
  • Mark S. Verratti, President-President Assurex Health (Age 47)
  • Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board (Age 85)
  • R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer (Age 46)
  • Alexander Ford, President of Myriad Genetic Laboratories, Inc. (Age 50)
  • Ralph L. McDade Ph.D., President of Myriad RBM, Inc (Age 62)
  • Bernard F. Tobin, President of Crescendo Bioscience, Inc (Age 55)
  • Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary (Age 59)
  • Gary A. King, Executive Vice President - International Operations (Age 61)

Who owns Myriad Genetics stock?

Myriad Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (14.04%), Dimensional Fund Advisors LP (5.17%), Frontier Capital Management Co. LLC (3.88%), Disciplined Growth Investors Inc. MN (1.95%), Russell Investments Group Ltd. (1.66%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Sterling Capital Management LLC, First Trust Advisors LP, Frontier Capital Management Co. LLC, Canada Pension Plan Investment Board, BB&T Corp, Piedmont Investment Advisors LLC, Chartwell Investment Partners LLC and American Century Companies Inc.. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford and John T Henderson. View Insider Buying and Selling for Myriad Genetics.

Who bought Myriad Genetics stock? Who is buying Myriad Genetics stock?

Myriad Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Caisse DE Depot ET Placement DU Quebec, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Russell Investments Group Ltd., Fisher Asset Management LLC, Parsec Financial Management Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of Myriad Genetics stock can currently be purchased for approximately $32.88.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $2.31 billion and generates $771.4 million in revenue each year. The company earns $21.8 million in net income (profit) each year or $1.48 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 S Wakara Way, SALT LAKE CITY, UT 84108-1214, United States. The company can be reached via phone at +1-801-5843600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  448 (Vote Underperform)
Total Votes:  713
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Myriad Genetics (NASDAQ:MYGN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 1.90)
Consensus Price Target: $26.56 (19.23% downside)

Consensus Price Target History for Myriad Genetics (NASDAQ:MYGN)

Price Target History for Myriad Genetics (NASDAQ:MYGN)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Deutsche Bank AGBoost Price TargetHold$28.00 -> $30.00N/AView Rating Details
11/8/2017Morgan StanleyBoost Price TargetUnderweight$24.00 -> $26.00N/AView Rating Details
10/2/2017Leerink SwannReiterated RatingMkt Perform -> Market Perform$31.00MediumView Rating Details
9/22/2017StephensReiterated RatingOverweight$36.00 -> $40.00LowView Rating Details
9/17/2017Cowen and CompanyReiterated RatingHold$25.00LowView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingHold$21.00 -> $23.00HighView Rating Details
8/9/2017Barclays PLCLower Price TargetEqual Weight$28.00 -> $26.00HighView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00LowView Rating Details
6/30/2017J P Morgan Chase & CoReiterated RatingUnderweight$16.00LowView Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralN/AView Rating Details
10/10/2016Bank of America CorporationReiterated RatingSellN/AView Rating Details
8/21/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00N/AView Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00N/AView Rating Details
3/23/2016The Goldman Sachs Group, Inc.Boost Price Target$40.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Myriad Genetics (NASDAQ:MYGN)

Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)

Earnings History by Quarter for Myriad Genetics (NASDAQ MYGN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
11/7/2017Q1 2018$0.21$0.26$183.52 million$190.20 millionViewN/AView Earnings Details
8/8/2017Q4 17$0.26$0.30$193.71 million$200.50 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.24$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
2017 EPS Consensus Estimate: $1.25
2018 EPS Consensus Estimate: $0.98
2019 EPS Consensus Estimate: $1.15
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.25$0.42$0.31
Q2 20173$0.23$0.46$0.33
Q3 20173$0.24$0.43$0.31
Q4 20173$0.26$0.38$0.30
Q1 20183$0.19$0.21$0.20
Q2 20183$0.22$0.23$0.23
Q3 20183$0.24$0.26$0.25
Q4 20183$0.29$0.31$0.30
Q1 20193$0.26$0.27$0.27
Q2 20193$0.24$0.28$0.27
Q3 20193$0.29$0.30$0.29
Q4 20193$0.31$0.34$0.32
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Myriad Genetics (NASDAQ MYGN)

Insider Ownership Percentage: 6.70%
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Insider Trades by Quarter for Myriad Genetics (NASDAQ MYGN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017Alexander FordInsiderSell3,031$31.64$95,900.84View SEC Filing  
9/1/2017John T HendersonDirectorSell30,000$30.30$909,000.00View SEC Filing  
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.00View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Myriad Genetics (NASDAQ:MYGN)

Latest Headlines for Myriad Genetics (NASDAQ MYGN)

Source:
DateHeadline
Heres Why Investors Should Buy Myriad Genetics Right Now - NasdaqHere's Why Investors Should Buy Myriad Genetics Right Now - Nasdaq
www.nasdaq.com - November 18 at 6:22 AM
 Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $188.75 Million Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $188.75 Million
www.americanbankingnews.com - November 17 at 6:26 PM
Quest Diagnostics, Clinical Genomics Ally, Oncology Strong - NasdaqQuest Diagnostics, Clinical Genomics Ally, Oncology Strong - Nasdaq
www.nasdaq.com - November 15 at 6:38 AM
Ophthotech (OPHT) Jumps: Stock Rises 11.9%Ophthotech (OPHT) Jumps: Stock Rises 11.9%
finance.yahoo.com - November 15 at 6:38 AM
Zacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Announce Earnings of $0.24 Per ShareZacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Announce Earnings of $0.24 Per Share
www.americanbankingnews.com - November 15 at 1:22 AM
Alexander Ford Sells 3,031 Shares of Myriad Genetics, Inc. (MYGN) StockAlexander Ford Sells 3,031 Shares of Myriad Genetics, Inc. (MYGN) Stock
www.americanbankingnews.com - November 14 at 8:54 PM
William Blair Comments on Myriad Genetics, Inc.s Q2 2018 Earnings (MYGN)William Blair Comments on Myriad Genetics, Inc.'s Q2 2018 Earnings (MYGN)
www.americanbankingnews.com - November 14 at 10:23 AM
Corporate News Blog - Myriad Teams Up with Department of Veterans Affairs for Clinical Trials to Evaluate the Effectiveness of GeneSight(R) Test in Improving MDD In VeteransCorporate News Blog - Myriad Teams Up with Department of Veterans Affairs for Clinical Trials to Evaluate the Effectiveness of GeneSight(R) Test in Improving MDD In Veterans
finance.yahoo.com - November 14 at 3:17 AM
A Myriad Of Growth? - Seeking AlphaA Myriad Of Growth? - Seeking Alpha
seekingalpha.com - November 12 at 9:41 AM
Myriad Genetics, Inc. (MYGN) Upgraded at ValuEngineMyriad Genetics, Inc. (MYGN) Upgraded at ValuEngine
www.americanbankingnews.com - November 11 at 2:56 PM
Myriad Genetics to Present at the 2017 Jefferies London Healthcare ConferenceMyriad Genetics to Present at the 2017 Jefferies London Healthcare Conference
feeds.benzinga.com - November 9 at 6:52 PM
Jefferies Group Analysts Lower Earnings Estimates for Myriad Genetics, Inc. (MYGN)Jefferies Group Analysts Lower Earnings Estimates for Myriad Genetics, Inc. (MYGN)
www.americanbankingnews.com - November 9 at 12:40 PM
Leerink Swann Analysts Cut Earnings Estimates for Myriad Genetics, Inc. (MYGN)Leerink Swann Analysts Cut Earnings Estimates for Myriad Genetics, Inc. (MYGN)
www.americanbankingnews.com - November 9 at 12:40 PM
Myriad Genetics Inc. Q1 Income Climbs 14% - Nasdaq.com - NasdaqMyriad Genetics Inc. Q1 Income Climbs 14% - Nasdaq.com - Nasdaq
www.nasdaq.com - November 9 at 6:46 AM
Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues - NasdaqMyriad Genetics (MYGN) Beats on Q1 Earnings & Revenues - Nasdaq
www.nasdaq.com - November 9 at 6:46 AM
Edited Transcript of MYGN earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of MYGN earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:46 AM
Myriad Genetics, Inc. (MYGN) Announces  Earnings ResultsMyriad Genetics, Inc. (MYGN) Announces Earnings Results
www.americanbankingnews.com - November 7 at 7:27 PM
Myriad Genetics, Inc. (MYGN) Updates FY18 Earnings GuidanceMyriad Genetics, Inc. (MYGN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - November 7 at 5:48 PM
Myriad Genetics, Inc. (MYGN) Releases Q2 Earnings GuidanceMyriad Genetics, Inc. (MYGN) Releases Q2 Earnings Guidance
www.americanbankingnews.com - November 7 at 5:48 PM
Myriad Genetics Reports Fiscal First-Quarter 2018 Financial ResultsMyriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
feeds.benzinga.com - November 7 at 4:43 PM
Myriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED ... - GlobeNewswire (press release)Myriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED ... - GlobeNewswire (press release)
globenewswire.com - November 7 at 7:15 AM
Myriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the Vectra® DA TestMyriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the Vectra® DA Test
finance.yahoo.com - November 7 at 7:15 AM
Myriad Genetics, Inc. – Value Analysis (NASDAQ:MYGN) : November 6, 2017Myriad Genetics, Inc. – Value Analysis (NASDAQ:MYGN) : November 6, 2017
finance.yahoo.com - November 7 at 7:15 AM
RSI Alert: Myriad Genetics (MYGN) Now OversoldRSI Alert: Myriad Genetics (MYGN) Now Oversold
www.nasdaq.com - November 4 at 6:53 AM
Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive DisorderMyriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
finance.yahoo.com - November 4 at 6:53 AM
Here's Why Myriad Genetics Dropped as Much as 18.6%Here's Why Myriad Genetics Dropped as Much as 18.6%
finance.yahoo.com - November 4 at 6:53 AM
Todays Research Reports on Trending Tickers: Omeros Corporation and Myriad GeneticsToday's Research Reports on Trending Tickers: Omeros Corporation and Myriad Genetics
finance.yahoo.com - November 4 at 6:53 AM
Myriad Genetics, Inc. breached its 50 day moving average in a Bearish Manner : MYGN-US : November 3, 2017Myriad Genetics, Inc. breached its 50 day moving average in a Bearish Manner : MYGN-US : November 3, 2017
finance.yahoo.com - November 4 at 6:52 AM
Myriad Genetics, Inc. (MYGN) Downgraded by ValuEngine to HoldMyriad Genetics, Inc. (MYGN) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - November 3 at 12:14 AM
Heres Why Myriad Genetics Dropped as Much as 18.6%Here's Why Myriad Genetics Dropped as Much as 18.6%
www.fool.com - November 2 at 3:25 PM
Can Molecular Diagnostics Drive Myriads (MYGN) Q1 Earnings?Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
finance.yahoo.com - November 1 at 6:35 AM
Myriad Genetics, Inc. (MYGN) Set to Announce Quarterly Earnings on TuesdayMyriad Genetics, Inc. (MYGN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 1:56 PM
Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting - GlobeNewswire (press release)Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting - GlobeNewswire (press release)
globenewswire.com - October 31 at 6:42 AM
Can Molecular Diagnostics Drive Myriads (MYGN) Q1 Earnings? - NasdaqCan Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings? - Nasdaq
www.nasdaq.com - October 31 at 6:41 AM
Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual MeetingCrescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
finance.yahoo.com - October 31 at 6:41 AM
Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual MeetingCrescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
finance.yahoo.com - October 31 at 6:41 AM
Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
finance.yahoo.com - October 31 at 6:41 AM
Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
finance.yahoo.com - October 31 at 6:41 AM
Myriad Genetics, Inc. (MYGN) Receives Consensus Rating of "Hold" from BrokeragesMyriad Genetics, Inc. (MYGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 29 at 5:38 AM
ETFs with exposure to Myriad Genetics, Inc. : October 27, 2017ETFs with exposure to Myriad Genetics, Inc. : October 27, 2017
finance.yahoo.com - October 28 at 8:33 AM
Myriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $182.34 MillionMyriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $182.34 Million
www.americanbankingnews.com - October 27 at 9:38 AM
Myriad Genetics (MYGN) Announces EndoPredict Shown in Second Study to be More Effective than Oncotype DX in ... - StreetInsider.comMyriad Genetics (MYGN) Announces EndoPredict Shown in Second Study to be More Effective than Oncotype DX in ... - StreetInsider.com
www.streetinsider.com - October 27 at 8:17 AM
EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Breast Cancer RecurrenceEndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Breast Cancer Recurrence
finance.yahoo.com - October 27 at 8:17 AM
Featured Company News - Myriad Submitted BRACAnalysis CDx Application Seeking Regulatory Approval in Japan for HER2 - Metastatic Breast CancerFeatured Company News - Myriad Submitted BRACAnalysis CDx Application Seeking Regulatory Approval in Japan for HER2 - Metastatic Breast Cancer
finance.yahoo.com - October 27 at 8:17 AM
Zacks: Analysts Anticipate Myriad Genetics, Inc. (MYGN) to Post $0.21 EPSZacks: Analysts Anticipate Myriad Genetics, Inc. (MYGN) to Post $0.21 EPS
www.americanbankingnews.com - October 25 at 2:04 PM
Myriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017 - GlobeNewswire (press release)Myriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017 - GlobeNewswire (press release)
globenewswire.com - October 25 at 7:52 AM
Myriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017Myriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017
finance.yahoo.com - October 25 at 7:52 AM
Myriad Genetics (MYGN) Announces Submission of BRACAnalysis CDx Application for Regulatory Approval in Japan ... - StreetInsider.comMyriad Genetics (MYGN) Announces Submission of BRACAnalysis CDx Application for Regulatory Approval in Japan ... - StreetInsider.com
www.streetinsider.com - October 24 at 7:26 AM
Myriad Submits BRACAnalysis® CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast CancerMyriad Submits BRACAnalysis® CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer
finance.yahoo.com - October 24 at 7:25 AM
Myriad Genetics, Inc. (MYGN) Set to Announce Earnings on MondayMyriad Genetics, Inc. (MYGN) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 23 at 12:32 PM

Social Media

Financials

Chart

Myriad Genetics (NASDAQ MYGN) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.